GDF15及其受体GFRAL在肥胖治疗上的相关研究进展

Research Progress of GDF15 and its Receptor GFRAL in the Treatment of Obesity

肥胖症是一种由于营养物质过剩导致体内脂肪堆积而引起的代谢性疾病,与糖尿病、心脏病等一系列疾病相关。近年来肥胖症的发病率不断攀升,严重威胁人类健康。药物是治疗肥胖症的重要手段,目前治疗肥胖症的药物多为小分子化学药物,存在较严重的副反应,亟待开发更加安全有效的新型药物。生长与分化因子15(GDF15)属于TGF-β超家族,是一类具有抗炎和抗细胞凋亡效应的细胞因子,近年来被发现具有强大的改善能量代谢和控制体重的作用,从而成为潜在治疗肥胖症的新型药物。简要综述了GDF15及其特异性受体——胶质细胞源性神经营养因子家族受体α相似蛋白(GFRAL)在治疗肥胖症中的研究进展。

Obesity is a metabolic disease caused by the accumulation of fat in body and threaten human health seriously. Obesity is associated with a serious of disease such as diabetes and heart disease. The incidence of obesity has risen continously in recent years. Drugs are important means for treating obesity and most of the drugs used to treat obesity are small molecule drugs which can cause many side effects. Therefore it is urgent to develop new drugs that are safer and more effective. Growth and differentiation factor 15（GDF15） is a member of the TGF-β supeffamily. As a noval adipokine, GDF15 shows many effects in anti-inflmmatory and anti-apoptosis. GDF15 has also been found powerful effects on improving energy metabolism and controlling body weight in recent years, which make it a potential new drug for treating obesity. We reviewed the mechanism and role of GDF15 and its specific receptor GFRAL in the treatment of obesity.